The effects of saponin on the binding and functional properties of the human adenosine A(1) receptor

被引:34
作者
Cohen, FR
Lazareno, S
Birdsall, NJM
机构
[1] NATL INST MED RES,DIV PHYS BIOCHEM,LONDON NW7 1AA,ENGLAND
[2] MRC,CTR COLLABORAT,LONDON NW7 1AD,ENGLAND
关键词
saponin; adenosine; adenosine A(1); receptors; receptor-G-protein coupling;
D O I
10.1111/j.1476-5381.1996.tb15316.x
中图分类号
R9 [药学];
学科分类号
1007 [药学];
摘要
1 Experiments with adenosine deaminase suggest that adenosine is present in membrane preparations from CHO cells bearing adenosine A(1) receptors. 2 Pretreatment of the membranes (ca 0.6 mg protein ml(-1)) with the permeabilizing agent saponin (100 mu g ml(-1)) or addition of saponin (10 mu g ml(-1)) to the membranes (0.02-0.08 mg protein ml(-1)) in the assay, generates homogeneous low affinity agonist binding curves in the presence of GTP and an increased function, assessed by agonist stimulation of [S-35]-GTP gamma S binding. The affinity constants for the binding of an agonist and an antagonist are not affected by this saponin treatment. Saponin facilitates the interaction of guanine nucleotides with receptor G-protein complexes, possibly by removing a permeability barrier to access of G-proteins by GTP. However, adenosine is still present in the binding assays after saponin treatment. 3 The agonist binding properties of the human A(1) receptor have been characterized. In saponin pretreated membranes, 80-90% of the A(1) receptors are capable of forming agonist-receptor-G protein complexes in the absence of GTP. These complexes have a 300-600 fold higher affinity than uncoupled receptors for N-6-cyclohexyladenosine. 4 A very slow component is observed in the association and dissociation kinetics of the agonist [H-3]-N-6-cyclohexyladenosine ([H-3]-CHA) and in the association but not dissociation kinetics of the antagonist [H-3]-8-cyclopentyl-1,3-dipropylxanthine ([H-3]-DPCPX). The slow association component of [H-3]-DPCPX is essentially absent when incubations are carried out in the presence of GTP. The slow dissociation component of [H-3]-CHA binding is rapidly disrupted by GTP. 5 It is hypothesized that long-lasting adenosine-receptor-G protein complexes are present in the CHO membrane preparations. The existence of these complexes, resistant to the action of adenosine deaminase but sensitive to GTP, may rationalize the observed kinetics and the increase in H-3-antagonist binding produced by GTP which has been observed in essentially all studies of A(1) receptors and has been ascribed previo usly to precoupling of A(1) receptors to G-proteins in the absence of agonists.
引用
收藏
页码:1521 / 1529
页数:9
相关论文
共 21 条
[1]
BURGESS GM, 1983, J BIOL CHEM, V258, P5336
[2]
Cohen Fiona, 1994, British Journal of Pharmacology, V112, p135P
[3]
DELEAN A, 1980, J BIOL CHEM, V255, P7108
[4]
AGONIST-INDEPENDENT INHIBITION OF G-PROTEIN ACTIVATION BY MUSCARINIC ACETYLCHOLINE-RECEPTOR ANTAGONISTS IN CARDIAC MEMBRANES [J].
HILF, G ;
JAKOBS, KH .
EUROPEAN JOURNAL OF PHARMACOLOGY-MOLECULAR PHARMACOLOGY SECTION, 1992, 225 (03) :245-252
[5]
MUSCARINIC ACETYLCHOLINE RECEPTOR-STIMULATED BINDING OF GUANOSINE 5'-O-(3-THIOTRIPHOSPHATE) TO GUANINE-NUCLEOTIDE-BINDING PROTEINS IN CARDIAC MEMBRANES [J].
HILF, G ;
GIERSCHIK, P ;
JAKOBS, KH .
EUROPEAN JOURNAL OF BIOCHEMISTRY, 1989, 186 (03) :725-731
[6]
HULME EC, 1992, RECEPTOR LIGAND INTE, P63
[7]
THE FUNCTION OF A HIGHLY-CONSERVED ARGININE RESIDUE IN ACTIVATION OF THE MUSCARINIC M(1) RECEPTOR [J].
JONES, PG ;
CURTIS, CAM ;
HULME, EC .
EUROPEAN JOURNAL OF PHARMACOLOGY-MOLECULAR PHARMACOLOGY SECTION, 1995, 288 (03) :251-257
[8]
GUANINE-NUCLEOTIDE EFFECTS ON 8-CYCLOPENTYL-1,3-[H-3]DIPROPYLXANTHINE BINDING TO MEMBRANE-BOUND AND SOLUBILIZED A1-ADENOSINE RECEPTORS OF RAT-BRAIN [J].
KLOTZ, KN ;
KEIL, R ;
ZIMMER, FJ ;
SCHWABE, U .
JOURNAL OF NEUROCHEMISTRY, 1990, 54 (06) :1988-1994
[9]
PHARMACOLOGICAL CHARACTERIZATION OF GUANINE-NUCLEOTIDE EXCHANGE-REACTIONS IN MEMBRANES FROM CHO CELLS STABLY TRANSFECTED WITH HUMAN MUSCARINIC RECEPTORS M1-M4 [J].
LAZARENO, S ;
FARRIES, T ;
BIRDSALL, NJM .
LIFE SCIENCES, 1993, 52 (5-6) :449-456
[10]
LEUNG E, 1990, MOL PHARMACOL, V38, P72